论文部分内容阅读
甲型肝炎(简称甲肝)是一种由甲肝病毒(HAV)引起的以肝脏损伤为主的严重急性传染病。长期以来甲肝的发病率始终居各种病毒性肝炎发病率的首位。据粗略估计,全世界有40亿人受到甲肝疾病的严重威胁,仅我国就有约4亿人为甲肝易感者。我国作为世界上最大的发展中国家,也是甲肝流行最严重的地区之一。所以研究特异性的免疫手段,发展稳定性好的甲型肝炎疫苗是唯一安全有效的措施。长春生物制品研究所的甲肝课题组的
Hepatitis A (Hepatitis A) is a severe acute infectious disease mainly caused by hepatitis A virus (HAV). For a long time the incidence of hepatitis A has always ranked first in the incidence of various viral hepatitis. According to a rough estimate, 4 billion people in the world are seriously threatened with hepatitis A disease, and only about 400 million people in our country are susceptible to hepatitis A. As the largest developing country in the world, our country is also one of the areas with the most serious hepatitis A epidemic. Therefore, the study of specific means of immunization, the development of good stability of hepatitis A vaccine is the only safe and effective measures. Changchun Institute of Biological Hepatitis A research group